A citation-based method for searching scientific literature

Lun Cai, Zheng Zhang, Lin Zhou, Haiyan Wang, Junliang Fu, Shuye Zhang, Min Shi, Hui Zhang, Yongping Yang, Hao Wu, Po Tien, Fu-Sheng Wang. Clin Immunol 2008
Times Cited: 168







List of co-cited articles
1193 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor.
Bastian Hoechst, Torsten Voigtlaender, Lars Ormandy, Jaba Gamrekelashvili, Fei Zhao, Heiner Wedemeyer, Frank Lehner, Michael P Manns, Tim F Greten, Firouzeh Korangy. Hepatology 2009
383
45

Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions.
Yan Wu, Dong-Ming Kuang, Wei-Dong Pan, Yun-Le Wan, Xiang-Ming Lao, Dian Wang, Xue-Feng Li, Limin Zheng. Hepatology 2013
139
29

Sorafenib in advanced hepatocellular carcinoma.
Josep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean-Frédéric Blanc, Andre Cosme de Oliveira, Armando Santoro, Jean-Luc Raoul, Alejandro Forner,[...]. N Engl J Med 2008
24

Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma.
Valerie Chew, Jinmiao Chen, Deming Lee, Evelyn Loh, Joyce Lee, Kiat Hon Lim, Achim Weber, Ksenija Slankamenac, Ronnie T P Poon, Henry Yang,[...]. Gut 2012
206
24

Natural killer cells in liver disease.
Zhigang Tian, Yongyan Chen, Bin Gao. Hepatology 2013
175
22

Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy.
Cheng Sun, Hao-yu Sun, Wei-hua Xiao, Cai Zhang, Zhi-gang Tian. Acta Pharmacol Sin 2015
87
21

Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas.
Masahisa Jinushi, Tetsuo Takehara, Tomohide Tatsumi, Naoki Hiramatsu, Ryotaro Sakamori, Shinjiro Yamaguchi, Norio Hayashi. J Hepatol 2005
158
18

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
Anthony B El-Khoueiry, Bruno Sangro, Thomas Yau, Todd S Crocenzi, Masatoshi Kudo, Chiun Hsu, Tae-You Kim, Su-Pin Choo, Jörg Trojan, Theodore H Welling,[...]. Lancet 2017
17

Human liver-resident CD56(bright)/CD16(neg) NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways.
Kelly Hudspeth, Matteo Donadon, Matteo Cimino, Elena Pontarini, Paolo Tentorio, Max Preti, Michelle Hong, Antonio Bertoletti, Silvio Bicciato, Pietro Invernizzi,[...]. J Autoimmun 2016
135
16

High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer.
Cheng Sun, Jing Xu, Qiang Huang, Mei Huang, Hao Wen, Chuanshan Zhang, Jinyu Wang, Jiaxi Song, Meijuan Zheng, Haoyu Sun,[...]. Oncoimmunology 2016
94
17

IL-15 Overcomes Hepatocellular Carcinoma-Induced NK Cell Dysfunction.
Nicholas J W Easom, Kerstin A Stegmann, Leo Swadling, Laura J Pallett, Alice R Burton, Dennis Odera, Nathalie Schmidt, Wei-Chen Huang, Giuseppe Fusai, Brian Davidson,[...]. Front Immunol 2018
43
34

Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO.
Tuanjie Li, Yang Yang, Xuefeng Hua, Guoying Wang, Wei Liu, Changchang Jia, Yan Tai, Qi Zhang, Guihua Chen. Cancer Lett 2012
159
14

CXCR6 marks a novel subset of T-bet(lo)Eomes(hi) natural killer cells residing in human liver.
Kerstin A Stegmann, Francis Robertson, Navjyot Hansi, Upkar Gill, Celeste Pallant, Theodoros Christophides, Laura J Pallett, Dimitra Peppa, Claire Dunn, Giuseppe Fusai,[...]. Sci Rep 2016
133
14

Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells.
Martin Franz Sprinzl, Florian Reisinger, Andreas Puschnik, Marc Ringelhan, Kerstin Ackermann, Daniel Hartmann, Matthias Schiemann, Arndt Weinmann, Peter Robert Galle, Marcus Schuchmann,[...]. Hepatology 2013
92
14

Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections.
Barbara Oliviero, Stefania Varchetta, Enrica Paudice, Giuseppe Michelone, Marco Zaramella, Domenico Mavilio, Francesca De Filippi, Savino Bruno, Mario U Mondelli. Gastroenterology 2009
303
13

Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.
Junliang Fu, Dongping Xu, Zhenwen Liu, Ming Shi, Ping Zhao, Baoyun Fu, Zheng Zhang, Huiyin Yang, Hui Zhang, Chunbao Zhou,[...]. Gastroenterology 2007
531
13

Liver-infiltrating CD11b-CD27- NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression.
Qiong-Fang Zhang, Wen-Wei Yin, Yang Xia, Ya-Yang Yi, Qiu-Feng He, Xing Wang, Hong Ren, Da-Zhi Zhang. Cell Mol Immunol 2017
61
21

Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients.
Valerie Chew, Charlene Tow, Marissa Teo, Hing Lok Wong, Jasmine Chan, Adam Gehring, Marie Loh, Alexandre Bolze, Richard Quek, Victor K M Lee,[...]. J Hepatol 2010
170
13

Functions of natural killer cells.
Eric Vivier, Elena Tomasello, Myriam Baratin, Thierry Walzer, Sophie Ugolini. Nat Immunol 2008
13

Tissue-resident Eomes(hi) T-bet(lo) CD56(bright) NK cells with reduced proinflammatory potential are enriched in the adult human liver.
Cathal Harmon, Mark W Robinson, Ronan Fahey, Sarah Whelan, Diarmaid D Houlihan, Justin Geoghegan, Cliona O'Farrelly. Eur J Immunol 2016
72
18

Innate or adaptive immunity? The example of natural killer cells.
Eric Vivier, David H Raulet, Alessandro Moretta, Michael A Caligiuri, Laurence Zitvogel, Lewis L Lanier, Wayne M Yokoyama, Sophie Ugolini. Science 2011
13

Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9.
Keisuke Kohga, Tetsuo Takehara, Tomohide Tatsumi, Hisashi Ishida, Takuya Miyagi, Atsushi Hosui, Norio Hayashi. Hepatology 2010
97
12

Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.
Qiang Gao, Shuang-Jian Qiu, Jia Fan, Jian Zhou, Xiao-Ying Wang, Yong-Sheng Xiao, Yang Xu, Yi-Wei Li, Zhao-You Tang. J Clin Oncol 2007
753
12

A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.
Bastian Hoechst, Lars A Ormandy, Matthias Ballmaier, Frank Lehner, Christine Krüger, Michael P Manns, Tim F Greten, Firouzeh Korangy. Gastroenterology 2008
553
12

Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans.
Kohei Ishiyama, Hideki Ohdan, Masahiro Ohira, Hiroshi Mitsuta, Koji Arihiro, Toshimasa Asahara. Hepatology 2006
121
12

Targeting natural killer cells in cancer immunotherapy.
Camille Guillerey, Nicholas D Huntington, Mark J Smyth. Nat Immunol 2016
517
12

Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Takahiro Kamiya, Yu-Hsiang Chang, Dario Campana. Cancer Immunol Res 2016
50
24

Controlling natural killer cell responses: integration of signals for activation and inhibition.
Eric O Long, Hun Sik Kim, Dongfang Liu, Mary E Peterson, Sumati Rajagopalan. Annu Rev Immunol 2013
678
12

Cutting edge: identification and characterization of human intrahepatic CD49a+ NK cells.
Nicole Marquardt, Vivien Béziat, Sanna Nyström, Julia Hengst, Martin A Ivarsson, Eliisa Kekäläinen, Helene Johansson, Jenny Mjösberg, Magnus Westgren, Tim O Lankisch,[...]. J Immunol 2015
157
12

Liver: An organ with predominant innate immunity.
Bin Gao, Won-Il Jeong, Zhigang Tian. Hepatology 2008
525
12


Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity.
Qing Zhang, Jiacheng Bi, Xiaodong Zheng, Yongyan Chen, Hua Wang, Wenyong Wu, Zhengguang Wang, Qiang Wu, Hui Peng, Haiming Wei,[...]. Nat Immunol 2018
341
12

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Masatoshi Kudo, Richard S Finn, Shukui Qin, Kwang-Hyub Han, Kenji Ikeda, Fabio Piscaglia, Ari Baron, Joong-Won Park, Guohong Han, Jacek Jassem,[...]. Lancet 2018
12

Deficient Natural Killer Cell NKp30-Mediated Function and Altered NCR3 Splice Variants in Hepatocellular Carcinoma.
Stefania Mantovani, Barbara Oliviero, Andrea Lombardi, Stefania Varchetta, Dalila Mele, Angelo Sangiovanni, Giorgio Rossi, Matteo Donadon, Guido Torzilli, Cristiana Soldani,[...]. Hepatology 2019
27
44

Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
Joon Hyeok Lee, Jeong-Hoon Lee, Young-Suk Lim, Jong Eun Yeon, Tae-Jin Song, Su Jong Yu, Geum-Youn Gwak, Kang Mo Kim, Yoon Jun Kim, Jae Won Lee,[...]. Gastroenterology 2015
235
11

A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.
Bruno Sangro, Carlos Gomez-Martin, Manuel de la Mata, Mercedes Iñarrairaegui, Elena Garralda, Pilar Barrera, Jose Ignacio Riezu-Boj, Esther Larrea, Carlos Alfaro, Pablo Sarobe,[...]. J Hepatol 2013
521
11

Liver-resident NK cells confer adaptive immunity in skin-contact inflammation.
Hui Peng, Xiaojun Jiang, Yonglin Chen, Dorothy K Sojka, Haiming Wei, Xiang Gao, Rui Sun, Wayne M Yokoyama, Zhigang Tian. J Clin Invest 2013
326
11

Natural killer cells phenotypic characterization as an outcome predictor of HCV-linked HCC after curative treatments.
Elisabetta Cariani, Massimo Pilli, Valeria Barili, Emanuela Porro, Elisabetta Biasini, Andrea Olivani, Raffaele Dalla Valle, Tommaso Trenti, Carlo Ferrari, Gabriele Missale. Oncoimmunology 2016
25
44

Diminished absolute counts of CD56dim and CD56bright natural killer cells in peripheral blood from Egyptian patients with hepatocellular carcinoma.
Amal Fathy, Mohamed Mohy Eldin, Lobna Metwally, Mohamed Eida, Marwa Abdel-Rehim. Egypt J Immunol 2009
16
68

Antigen-presenting cell function in the tolerogenic liver environment.
Angus W Thomson, Percy A Knolle. Nat Rev Immunol 2010
450
10

Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma.
Tobias Flecken, Nathalie Schmidt, Sandra Hild, Emma Gostick, Oliver Drognitz, Robert Zeiser, Peter Schemmer, Helge Bruns, Thomas Eiermann, David A Price,[...]. Hepatology 2014
195
10

Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma.
Lars A Ormandy, Tina Hillemann, Heiner Wedemeyer, Michael P Manns, Tim F Greten, Firouzeh Korangy. Cancer Res 2005
468
10

TGF-β1 down-regulation of NKG2D/DAP10 and 2B4/SAP expression on human NK cells contributes to HBV persistence.
Cheng Sun, Binqing Fu, Yufeng Gao, Xiaofeng Liao, Rui Sun, Zhigang Tian, Haiming Wei. PLoS Pathog 2012
131
10


Immune surveillance by the liver.
Craig N Jenne, Paul Kubes. Nat Immunol 2013
499
10


Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Andrew X Zhu, Richard S Finn, Julien Edeline, Stephane Cattan, Sadahisa Ogasawara, Daniel Palmer, Chris Verslype, Vittorina Zagonel, Laetitia Fartoux, Arndt Vogel,[...]. Lancet Oncol 2018
887
10

Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.
Shao-Lai Zhou, Zheng-Jun Zhou, Zhi-Qiang Hu, Xiao-Wu Huang, Zheng Wang, Er-Bao Chen, Jia Fan, Ya Cao, Zhi Dai, Jian Zhou. Gastroenterology 2016
272
10

Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation.
Veronika Groh, Jennifer Wu, Cassian Yee, Thomas Spies. Nature 2002
9



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.